7Baggers

We provide you with 20 years of free, institutional-grade data for LYEL stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of LYEL. Explore the full financial landscape of LYEL stock.

Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$133,702
NameActionSharesAvg PriceAmountReported Date
Hill Stephen J.Sale-1,004$10.54$10,5862025-08-22
Hill Stephen J.Grant, award...etc8,0002025-08-22
Seely LynnSale-7,257$10.54$76,5182025-08-22
Seely LynnGrant, award...etc40,0002025-08-22
Newton Charles W.Sale-1,453$10.54$15,3202025-08-22
Newton Charles W.Grant, award...etc8,0002025-08-22
Lee Gary K.Sale-1,453$10.54$15,3202025-08-22
Lee Gary K.Grant, award...etc8,0002025-08-22
Seely LynnSale-797$10.53$8,3892025-08-13
Newton Charles W.Sale-267$10.53$2,8102025-08-13
Lee Gary K.Sale-267$10.53$2,8102025-08-13
Hill Stephen J.Sale-185$10.53$1,9472025-08-13
Shook DavidGrant, award...etc21,9002025-06-11
BRAWLEY OTIS WOpen Market Purchase35,640$0.562025-04-02
Ramachandra SumantOpen Market Purchase200,000$0.582025-03-25
Klausner RichardOpen Market Purchase158,000$0.62025-03-18
Newton Charles W.Open Market Purchase200,000$0.562025-03-18
Seely LynnOpen Market Purchase175,000$0.612025-03-18
Lee Gary K.Grant, award...etc112,5002025-02-26
Newton Charles W.Grant, award...etc112,5002025-02-26
Hill Stephen J.Grant, award...etc112,5002025-02-26
Seely LynnGrant, award...etc337,5002025-02-26
Lang MatthewGrant, award...etc112,5002025-02-26
Hill Stephen J.Grant, award...etc40,0002024-02-13
Lang MatthewGrant, award...etc50,0002024-02-13
Lee Gary K.Grant, award...etc40,0002024-02-13
Seely LynnGrant, award...etc200,0002024-02-13
Newton Charles W.Grant, award...etc40,0002024-02-13
Klausner RichardSale-58,020$2.28$132,2862023-08-17
Klausner RichardSale-11,100$6.4$71,0412022-09-27
Bishop Hans EdgarDerivatives Exercise145,3802022-09-09
Login to see more insider transactions
The information provided in this report about LYEL stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

Lyell Immunopharma Inc
(NASDAQ:LYEL) 

LYEL stock logo

Lyell Immunopharma is an operator of a biotechnology company that develops cellular therapies to cure cancer. South San Francisco, California, United States.

Founded: 2018
Sector:
Industry:

Share this website to your friends